Unity Biotechnology, Inc. (UBX) Financials

UBX Assets vs Liabilities

DateAssetsLiabilities
March 31, 2025 30.3 million 30.6 million
Dec. 31, 2024 37.7 million 31.2 million
Sept. 30, 2024 47.1 million 33.0 million
June 30, 2024 53.5 million 33.8 million

UBX Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2025 -6.4 million 617000
Dec. 31, 2024 -5.9 million 805000
Sept. 30, 2024 -5.2 million 797000
June 30, 2024 -4.6 million 974000

UBX Net Income

No data available :(

UBX Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2025 16.9 million - 18.7 million
Dec. 31, 2024 23.2 million 19.7 million 23.5 million
Sept. 30, 2024 29.0 million 20.7 million 20.7 million
June 30, 2024 34.0 million 21.7 million 25.3 million

UBX Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2025 16.9 million
Dec. 31, 2024 16.8 million
Sept. 30, 2024 16.8 million
June 30, 2024 16.8 million

UBX Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2025 - 2.8 million 4.1 million 1.2 million
Dec. 31, 2024 - 935000 3.1 million -1.2 million
Sept. 30, 2024 - 2.8 million 3.8 million -
June 30, 2024 - 5.5 million 4.5 million 979000

UBX Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2025 - -664000
Dec. 31, 2024 - -664000
Sept. 30, 2024 - 216000
June 30, 2024 - 221000

UBX

Price: $0.20

52 week price:
0.20
3.10

Earnings Per Share: -1.63 USD

P/E Ratio: -0.18

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 71934

Market Capitalization: 5.0 million

Links: